- Rating
- 2
- Confidence
- 3
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
This paper proposes TARGEN for cancer-gene prioritization. It combines molecular and functional evidence, graph-based propagation, and a learned connection-partner structural score to rank candidate genes. The study evaluates pan-cancer and cancer-specific settings, reports ablations and network-rewiring analyses, derives a stationary-point interpretation of the structural component, and examines selected candidates using organoid dependency evidence.
Critical strengths
- The paper evaluates the added structural branch with an s = 0 ablation, label-retention controls, and degree-preserving network rewiring. Table 2 reports the highest mean AP in 15 of 16 cancer-specific tasks, which is a meaningful result within the evaluated benchmark.
- The cancer-specific evaluation and prescreened organoid analysis provide biological context. The authors also explicitly acknowledge transductive evaluation, unequal baseline resources, and the limited scope of the organoid follow-up.
Critical weaknesses
- The independent methodological novelty remains uncertain. Eqs. (9)–(10) relate the linear structural score to supervised residuals through a shared-neighborhood kernel under specified assumptions. The s = 0 ablation demonstrates a contribution within TARGEN, but does not distinguish this mechanism from resource-matched supervised graph-kernel or residual-propagation alternatives. Full-system comparisons also use different molecular and network resources.
- The favorable benchmark results do not yet establish generalization beyond the chosen labels and splits. Table 1 reports statistically significant gains of 0.278 percentage points in pan-cancer AP and 1.663 points in cancer-specific macro-average AP, with 14 of 16 individual cancers significant under the reported tests. However, the cancer-specific positives are DriverDB-derived computational candidates, 1,030 negative genes are shared across cancers, and evaluation is transductive. These design choices limit what can be inferred about robustness to alternative labels or unseen settings.
Questions for authors
- With identical molecular features, relation operators, gene coverage, and tuning budgets, how does the structural branch compare with supervised graph-kernel, label-propagation, and residual-correction alternatives?
- How sensitive are the results to alternative negative definitions and splits that separate related gene families or temporal evidence sources?
- Can the prescreened organoid candidates be compared with baseline-ranked candidates under the same selection and validation protocol?
2 comments
Thank you for the additional experiments and clarifications. I appreciate the authors' efforts, but I remain unconvinced by the rebuttal. My main concern is still the methodological contribution. The additional ablations show some benefit from the structural component, but they do not sufficiently clarify what is fundamentally new compared with existing graph-based approaches. The reported structural gains are also relatively modest, making it difficult to judge the importance of this component.
Overall, the rebuttal provides more experimental evidence, but my main concerns about novelty and generalization remain. I will therefore keep my original rating.
Methodological Contribution and Generalization Results
Thank you for your constructive comments on our methodological contribution and generalization evaluation. We have revised the main text accordingly. TARGEN integrates direct molecular and functional scores, their propagation, and label-trained connection-partner contributions. Full AP is 0.921 versus 0.869 for molecular-only and 0.906 for direct molecular and gene-set scoring; the isolated structural gain across 16 cancers is 1.109 percentage points (Tables I.1 and J.2). We appreciate the suggestion of a same-feature, same-graph kernel comparison, which remains a separate control beyond these reported experiments; Equation (10) concerns the fixed-operator linear setting. We have also added the CGMap comparison using shared numerical molecular inputs, labels, and folds, giving AP 0.9208 for TARGEN and 0.8580 for CGMap-CPDB (Table 3). Each method retains its graph and functional resources. DriverDB supplies target-cancer positives; reference negatives exclude positives across all 118 projects, leaving 1,030 common-coverage genes; all methods share labels and folds. NCG6 evaluation gives macro AP 0.713 and a structural gain of 1.189 percentage points (Table J.3). With disjoint families in outer testing and inner validation, macro AP is 0.8581 for TARGEN, 0.8491 for its additive ablation, 0.7652 for DISFusion, 0.7688 for deepCDG, and 0.7553 for EMOGI (Table 5). The structural gain is 0.901 percentage points, with a 95% interval of [0.532, 1.261] and one-sided p<0.05; Tables J.6 and J.7 also report class-count-matched random comparisons. Under the common organoid protocol, macro P@100 is 0.50%, 2.00%, 2.50%, and 2.50% for TARGEN, DISFusion, deepCDG, and EMOGI, respectively (Table H.6). Original-prescreening EAC replication counts are 1/4, 2/9, 3/5, and 2/4, respectively (Table H.7). Tables H.8 to H.12 retain matched backgrounds, Top200 results, all five contexts, and rank overlap, with source-data links in the reviewer guide.